ALT

Business Context and Reporting Period

Company: PharmAthene, Inc. (Note: Input metadata referenced Altimmune, Inc., but the filing text is for PharmAthene, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2008
Business Overview: PharmAthene is a biodefense company developing medical countermeasures against biological and chemical weapons. Key product candidates include SparVax (anthrax vaccine), Valortim (anthrax monoclonal antibody), Protexia (nerve agent countermeasure), and RypVax (plague vaccine).
Major Event: On April 2, 2008, the Company completed the acquisition of Avecia Biologics Limited's vaccines business (the "Avecia Acquisition") for approximately $18.6 million, adding SparVax and RypVax to its portfolio.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased significantly ($8.6 million for the quarter; $11.5 million for the six months) primarily due to the inclusion of acquired NIAID contracts for SparVax and RypVax following the Avecia Acquisition.
• Operating Expenses: Total operating expenses rose to $32.5 million for the quarter (from $7.1 million in 2007) and $43.3 million for the six months (from $12.9 million in 2007). This increase was driven by a one-time $15.9 million charge for acquired in-process research and development (IPR&D) and higher R&D costs for new programs.
• Cash Position: Cash and cash equivalents decreased by $26.4 million from December 31, 2007, to June 30, 2008. This reduction was primarily due to the $10 million cash payment for the Avecia Acquisition, funding a $7 million letter of credit, and operational cash burn.
• Debt Structure: The Company maintains a $10 million credit facility (11.5% interest) and $12.3 million in 8% convertible notes. A loan modification agreement requires the Company to maintain restricted cash equal to 1.25x its obligations to lenders.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management states that at the current rate of cash consumption, the Company will need to engage in financing transactions no later than the end of the first quarter of 2009. There is no assurance that funding will be available on acceptable terms.
• Government Dependence: Future revenues are heavily contingent on U.S. government contracts and grants. The Company notes that government contracts can be unilaterally cancelled or reduced.
• Development Risks: Product candidates are in various stages of development. Success depends on regulatory approvals (FDA), which are uncertain, particularly for biodefense products relying on the "Animal Rule" for efficacy data.
• Acquisition Contingencies: The Avecia Acquisition includes potential milestone payments totaling up to $23 million and royalties of 1%-2.5% of net sales, contingent on future contract awards and product sales.
• Going Concern: The Company has incurred cumulative net losses and expects to incur additional losses. Continuation as a going concern is dependent on the success of R&D programs and the ability to obtain adequate financing.

Key Facts for Investor Verification

• Financing Timeline: Verify the Company's ability to secure additional capital by Q1 2009 to avoid operational curtailment.
• Government Contract Status: Monitor the status of the RFP-BARDA-08015 for the Strategic National Stockpile (SparVax) and the renewal of the RypVax contract expiring in 2009.
• Debt Covenants: Confirm compliance with the loan modification agreement requiring restricted cash balances of 1.25x lender obligations.
• Deferred Consideration: Track the trigger for the $7 million deferred payment to Avecia (earlier of a $15 million financing or 18 months post-acquisition).
• Regulatory Milestones: Watch for FDA IND filing for Protexia (expected Q3 2008) and Phase I trial results for Valortim and RypVax.